Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Clinical Applications of Epidermal Stem Cells01:19

Clinical Applications of Epidermal Stem Cells

Epidermal stem cells (EpiSCs) are mainly located at the basal layer of the epidermis. These cells repair minor injuries of the skin and replace dead skin cells. However, EpiSCs’ cannot heal severe wounds such as major burns or those from diabetes or hereditary disorders. In such cases, culturing the epidermal stem cells from the patient is possible and has yielded successful treatment options, such as laboratory-grown skin grafts. These grafts are synthesized using a patient’s own EpiSCs...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Systemic lupus erythematosus patients eligible for chimeric antigen receptor T-cell therapy according to the 2024 EBMT and International Society for Cell and Gene Therapy expert-based recommendations: a 1-year clinical practice study in France.

Cytotherapy·2026
Same author

Effectiveness of SARS-CoV-2 vaccination program in systemic sclerosis patients treated by autologous haematopoietic stem cell transplantation: a comparative study on behalf of MATHEC-SFGM-TC group.

Clinical and experimental rheumatology·2026
Same author

Fate and function of exogenously administered mesenchymal stromal cells: current insights and future directions.

Cytotherapy·2025
Same author

Definition of relapse criteria in patients with rapidly progressive systemic sclerosis treated with autologous haemopoietic stem cell transplantation.

Bone marrow transplantation·2025
Same author

Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases.

Cytotherapy·2025
Same author

Autologous haematopoietic stem cell transplantation for rheumatic diseases: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee.

Bone marrow transplantation·2025

Related Experiment Video

Updated: Jun 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Autologous stem cell transplantation for systemic sclerosis.

Dominique Farge1, Richard Nash, Jacob M Laar

  • 1Service de Médecine Interne, Hopital Saint Louis, Paris, France. dominique.farge-bancel@sls.ap-hop-paris.fr

Autoimmunity
|October 30, 2008
PubMed
Summary

Hematopoietic stem cell transplantation (HSCT) offers sustained improvement in skin thickening and organ function for severe diffuse cutaneous systemic sclerosis (dcSSc) patients. This therapy shows promise for improving survival rates in this autoimmune disease.

More Related Videos

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Related Experiment Videos

Last Updated: Jun 28, 2026

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome
06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE
09:24

Systemic Injection of Neural Stem/Progenitor Cells in Mice with Chronic EAE

Published on: April 15, 2014

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity
10:10

Development of Stem Cell-derived Antigen-specific Regulatory T Cells Against Autoimmunity

Published on: November 8, 2016

Area of Science:

  • Rheumatology
  • Immunology
  • Hematology

Background:

  • Systemic sclerosis (SSc) is a severe autoimmune disease with high mortality, particularly the diffuse cutaneous form (dcSSc).
  • Current treatments for severe dcSSc have limited efficacy, necessitating novel therapeutic strategies.
  • Hematopoietic stem cell transplantation (HSCT) has emerged as a potential treatment for patients with poor prognoses.

Purpose of the Study:

  • To review the efficacy and safety of HSCT in patients with severe diffuse cutaneous systemic sclerosis (dcSSc).
  • To analyze the impact of HSCT on skin thickening, organ function, and survival rates.
  • To summarize findings from European and North American phase I-II studies and inform ongoing phase III trials.

Main Methods:

  • Review of short- and long-term data from European and North American phase I-II studies on HSCT for severe dcSSc.
  • Analysis of outcomes including skin involvement, major organ function, and survival.
  • Consideration of both autologous and allogeneic HSCT approaches.

Main Results:

  • Autologous HSCT demonstrated sustained improvement in skin thickening for up to seven years post-transplantation.
  • Stabilization of major organ function was observed in selected patients following HSCT.
  • HSCT shows promising effects on survival rates in patients with severe dcSSc.

Conclusions:

  • Autologous HSCT is a viable therapeutic option for selected patients with severe dcSSc, offering long-term benefits.
  • Ongoing phase III trials (ASTIS, SCOTT) will further evaluate the benefits of HSCT, with and without high-dose irradiation.
  • HSCT represents a significant advancement in managing severe systemic sclerosis.